Psychologist

  • STEP 1

    After you have logged in, navigate to the CPD Activities and Questionnaires tab where you will find the activities (as mentioned below) you have to complete.

    You will need 60 CEU’s for your audit to be compliant. A minimum of 10 CEU’s should be in the ethics category.

  • STEP 2

    Below is a list of all the activities available to complete.

    These cover a total of 81 CEU’s, and comprise 43 clinical, 17 ethics and 21 general CEU’s.

    1. If you already have a few CEU’s, complete any activities to make up for the CEU shortfall you need.

    OR

    1. If you currently have no CEU’s, complete any activities to make up for the 60 CEU’s you will need.

    HOWEVER, MAKE SURE THAT YOU COMPLETE THE MINIMUM REQUIRED ETHICS CEU’S

  • STEP 3

    When you have completed the necessary activities for your audit, please send an email or WhatsApp to notify us.

    (safocus@iafrica.com / 074 230 3874)

    We will confirm the correctness and then submit your CPD Individual Activity Record (IAR) on 29May2020 via email to the HPCSA and copy you in the email for your reference.

* Should you not finish before the 29th of May at 12h00 we will request for an extension on your behalf and send you an email with more details of the next steps.

Please contact us should you need more guidance.

CLINICAL
  • C1(19) – Daydreamer and Night Owl – PART 1
  • C1(19) – Daydreamer and Night Owl – PART 2
  • C2(19) – A proposed conceptualization of therapeutic competence: the three level model
  • C3(19) – Development of a short form of the compulsive internet use scale in Switzerland
  • C4(19) – Psychological and social risks to children of using internet: literature review
  • C5(19) – Measuring the ICD-11 adjustment disorder concept: validity and sensitivity to change the Adjustment Disorder – New model questionnaire in a clinical intervention study
  • C7(19) – Copying styles effect on stress and psychological well-being among individuals with chronic pain
  • C15(19) – Change during psychotherapy: the perspective of children and adolescents who have been sexually abused PART 1
  • C15(19) – Change during psychotherapy: the perspective of children and adolescents who have been sexually abused PART 2
  • C23(19) – Consistency and factorial invariance of the Davidson trauma scale in heterogeneous populations: results from the 2010 Chilean earthquake
  • C24(19) – Evidence for the reliability and preliminary validity of the Adult ADHD Self-Report Scale v1.1 (ASRS v1.1) Screener in an adolescent community sample
  • C25(19) – Examining item content validity using property fitting analysis via multidimensional scaling
  • C26(19) – The dimensionality of suicidal ideation and its clinical implications
  • C27(19) – Childhood IQ and survival to 79: follow-up of 94% of the Scottish Mental Survey 1947
  • C29(19) – The Post-Deployment Mental Health (PDMH) study and repository: A multi-site study of US Afghanistan and Iraq era veterans
ETHICS
  • PE1(20) Ethical guidelines on social media
  • PE1(19) – Advanced directives as a tool to respect patient’s values and preferences: discussion on the case of Alzheimer’s disease
  • PE2(19) – How technology impacts on the therapeutic relationship
  • PE3(20) – Digital pills: a scoping review of the empirical literature and analysis of the ethical aspects
  • PE5(20) – General ethical guidelines for good practice in telemedicine
GENERAL
  • G1(19) – Medicinal Cannabis: History, Pharmacology, And Implications for the Acute Care Setting
  • G1(20) Human trafficking – what the health care professional can do
  • G2(20) – Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
  • G2a(19) Update of cannabis and its medical use  History and Pharmacology Part 1 of 3
  • G2b(19) Update of cannabis and its medical use  Cannabis toxicity and dependence Part 2 of 3
  • G2c(19) Update of cannabis and its medical use  The use of cannabis for medical purposes Part 3 of 3
  • G3(20) – The psychological impact of quarantine and how to reduce it: rapid review of the evidence
  • G5(20) – Clinical management of suspected or confirmed COVID-19 disease